Bristol-Myers forms fibrotic disease biotech, bags buyout option

Bristol-Myers Squibb has created a fibrotic and inflammatory disease biotech through its partnership with BioMotiv. The biotech, Anteros Pharmaceuticals, starts life with materials from Bristol-Myers to support development of small molecules and the potential to land a takeover by the Big Pharma.